Elanco was originally a division of Eli Lilly, and Jeff Simmons currently serves as the President and CEO of Elanco.
9 reports, 2 independent
Updated Aug 17
Gone quiet
- Reports
- 9
- Developments
- 3
- Repetition
- 67%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Elanco was originally a division of Eli Lilly, and Jeff Simmons currently serves as the President and CEO of Elanco.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.Elanco's corporate history shows it was once a division of Eli Lilly, led by Jeff Simmons.1 source
Ascend is expected to drive efficiencies for Elanco, led by CEO Jeffrey N. Simmons.1 source
Elanco CEO Jeffrey Simmons highlighted growth driven by price and volume.1 source
Keep exploring
The entities involved
-
Jeff Simmons
American musician
Nothing else this week.
-
Elanco
American healthcare company
Nothing else this week.
-
Eli Lilly and Company
American pharmaceutical company
Coverage
Newest first; wire copies grouped- yahoo.com
- StockStoryUnpacking Q2 Earnings: Elanco (NYSE:ELAN) In The Context Of Other Pharmaceuticals Stocks Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its pee
- StockStory1 Healthcare Stock for Long-Term Investors and 2 We Ignore Personal health and wellness is one of the many secular tailwinds for healthcare companies. Despite the rosy long-term prospects, short-term
- StockStory5 Insightful Analyst Questions From Elanco’s Q2 Earnings Call Elanco’s second quarter results were well received by the market, reflecting both strong execution and momentum in its innovation-driven
- StockStoryELAN Q2 Deep Dive: Innovation and Execution Drive Raised Full-Year Outlook Animal health company Elanco (NYSE:ELAN) reported Q2 CY2025 results exceeding the market’s revenue expectations , with sales
- StockStoryElanco (NYSE:ELAN) Delivers Impressive Q2, Stock Jumps 15.4% Animal health company Elanco (NYSE:ELAN) reported revenue ahead of Wall Street’s expectations in Q2 CY2025, with sales up 4.8% year on yea
- StockStory1 Volatile Stock with Exciting Potential and 2 to Question Volatility cuts both ways - while it creates opportunities, it also increases risk, making sharp declines just as likely as big gains. This
- StockStory3 Profitable Stocks Facing Headwinds Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today doesn’t m